Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high ...
MedPage Today on MSN
Alcohol-related liver disease may be more common than we think
After adjusting for alcohol underreporting, prevalence doubled ...
Please provide your email address to receive an email when new articles are posted on . At least 60% of liver cancer diagnoses can be attributed to modifiable risk factors. Alcohol consumption and ...
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease—previously called ...
Altimmune, Inc. announced new analyses at the EASL Congress in Amsterdam, showcasing the MASH Resolution Index (MASHResInd) algorithm, developed by Dr. Rohit Loomba, to predict resolution in patients ...
Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.
Imagine sitting in a doctor’s office and being told you have “non-alcoholic” liver disease. Before the doctor even finishes explaining what that means, your brain is already doing gymnastics trying to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results